文献速递浆细胞疾病

循环肿瘤细胞用于多发性骨髓瘤全面多区域无创遗传学特征分析

Circulating tumor cells for comprehensive and multiregional non-invasive genetic characterization of multiple myeloma.
PubMed 文献 · Leukemia · 2020-06-01

研究纳入53例多发性骨髓瘤患者,用二代流式细胞术分离配对循环肿瘤细胞与骨髓肿瘤细胞并比较遗传学特征,8例另取髓外浆细胞瘤行全外显子测序。循环肿瘤细胞在全部患者外周血中可检出,约22%的循环肿瘤细胞来自与配对骨髓穿刺部位不同的骨髓或髓外部位。染色体臂水平拷贝数改变一致性≥95%,易位一致性39%,除1例t(4;14)外所有高危遗传学异常均在循环肿瘤细胞中检出,骨髓和髓外克隆中≥82%的突变可在循环肿瘤细胞中检出。

要点

  • 循环肿瘤细胞在全部多发性骨髓瘤患者外周血中可检出。
  • 循环肿瘤细胞与骨髓肿瘤细胞染色体臂水平拷贝数改变一致性≥95%,易位一致性39%。
  • 除1例t(4;14)外,骨髓中所有高危遗传学异常均可在循环肿瘤细胞中检出。

核心结论

  • 结果支持循环肿瘤细胞可基于其数量和遗传学特征用于多发性骨髓瘤患者的无创风险分层。

研究设计与样本

  • 研究用二代流式细胞术从53例多发性骨髓瘤患者分离配对的循环肿瘤细胞与骨髓肿瘤细胞并比较其遗传学特征。

主要发现

  • 循环肿瘤细胞在全部多发性骨髓瘤患者外周血中可被二代流式细胞术检出。
  • 根据克隆和亚克隆突变的癌细胞分数,约22%的循环肿瘤细胞来自与配对骨髓穿刺部位不同的骨髓或髓外部位。
  • 骨髓肿瘤细胞与循环肿瘤细胞染色体臂水平拷贝数改变一致性≥95%,而易位一致性为39%。
  • 除1例t(4;14)外,骨髓肿瘤细胞中存在的所有高危遗传学异常均可在循环肿瘤细胞中检出。
  • 骨髓和髓外克隆中≥82%的突变可在循环肿瘤细胞中检出。

关键数值与推荐

  • 8例患者另分选髓外浆细胞瘤肿瘤细胞并对三种空间分布的肿瘤样本行全外显子测序。
  • 染色体臂水平拷贝数改变一致性≥95%,易位一致性39%。
  • 骨髓和髓外克隆中≥82%的突变可在循环肿瘤细胞中检出。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Multiple myeloma (MM) patients undergo repetitive bone marrow (BM) aspirates for genetic characterization. Circulating tumor cells (CTCs) are detectable in peripheral blood (PB) of virtually all MM cases and are prognostic, but their applicability for noninvasive screening has been poorly investigated. Here, we used next-generation flow (NGF) cytometry to isolate matched CTCs and BM tumor cells from 53 patients and compared their genetic profile. In eight cases, tumor cells from extramedullary (EM) plasmacytomas were also sorted and whole-exome sequencing was performed in the three spatially distributed tumor samples. CTCs were detectable by NGF in the PB of all patients with MM. Based on the cancer cell fraction of clonal and subclonal mutations, we found that ~22% of CTCs egressed from a BM (or EM) site distant from the matched BM aspirate. Concordance between BM tumor cells and CTCs was high for chromosome arm-level copy number alterations (≥95%) though not for translocations (39%). All high-risk genetic abnormalities except one t(4;14) were detected in CTCs whenever present in BM tumor cells. Noteworthy, ≥82% mutations present in BM and EM clones were detectable in CTCs. Altogether, these results support CTCs for noninvasive risk-stratification of MM patients based on their numbers and genetic profile.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Garcés JJ, Bretones G, Burgos L, et al. Circulating tumor cells for comprehensive and multiregional non-invasive genetic characterization of multiple myeloma. Leukemia. 2020. PMID: 32475991. doi:10.1038/s41375-020-0883-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。